false
Catalog
2023 World Conference on Lung Cancer (Posters)
P2.03. Effectiveness and Safety of Combining Bevac ...
P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients - PDF(Abstract)
Back to course
Pdf Summary
This study aimed to assess the effectiveness and safety of combining bevacizumab and fractionated stereotactic radiotherapy (FSRT) for brain metastases in non-small cell lung cancer (NSCLC) patients with stable extracranial disease status. NSCLC patients with brain metastases were recruited and assigned to receive FSRT along with bevacizumab. The primary endpoint of the study was intra-cranial progression-free survival (IPFS), and the secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life (QOL) score, and toxicities. The control group consisted of patients treated with whole-brain radiotherapy (WBRT) plus FSRT or FSRT only. <br /><br />Results showed that the combination of FSRT and bevacizumab achieved promising intracranial disease control. The estimated 1-year IPFS and OS rates were 77.4% and 74.8% respectively. The median PFS was 8.4 months. The FSRT plus bevacizumab group had a significantly higher 1-year IPFS rate compared to the control groups. The treatment-related toxicities of FSRT plus bevacizumab were mild with low incidence, including reversible mild hypertension and cerebral radio-necrosis. No signs of extra-lesional hemorrhage or progression of peri-lesional edema were found. Additionally, significant improvement in QOL was observed in symptomatic patients.<br /><br />In conclusion, the combination of FSRT with bevacizumab was tolerable and achieved promising intracranial disease control in NSCLC patients. QOL was maintained with a low incidence of cerebral radio-necrosis. This study suggests that this combination therapy could be an effective option for NSCLC patients with brain metastases.
Asset Subtitle
Rui Zhou
Meta Tag
Speaker
Rui Zhou
Topic
Metastatic NSCLC: Local Therapies
Keywords
bevacizumab
fractionated stereotactic radiotherapy
brain metastases
non-small cell lung cancer
extracranial disease
intra-cranial progression-free survival
overall survival
progression-free survival
quality of life
toxicities
×
Please select your language
1
English